Physician profile
Jenifer E Taylor
NPI 1053960666
$9,650.54
in general payments reported to CMS, 2019-2025
52 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,287 · 2022: $2,035 · 2023: $2,636 · 2024: $1,982 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,255 · Education: $823 · Consulting Fee: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,255.05 |
| Education | $823.15 |
| Consulting Fee | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,002.48 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $920.89 | 2021-2025 | |
| Seagen INC. | $864.20 | 2021-2025 | Tukysa, Adcetris, Padcev |
| Janssen Biotech, INC. | $822.14 | 2021-2025 | Tecvayli, Darzalex, Erleada |
| Exelixis INC. | $559.49 | 2021-2025 | Cabometyx |
| Incyte Corporation | $461.18 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Glaxosmithkline, LLC. | $459.89 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $456.10 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $443.12 | 2021-2023 | Lumakras |
| E.R. Squibb & Sons, L.L.C. | $412.46 | 2021-2025 | Opdivo, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $338.39 | 2021-2025 | Enhertu, Injectafer |
| Regeneron Healthcare Solutions, INC. | $276.16 | 2023-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.68 | 2021-2024 | Gilotrif |
| Astrazeneca Pharmaceuticals LP | $216.53 | 2021-2025 | Tagrisso, Enhertu |
| Genzyme Corporation | $188.71 | 2021-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $179.95 | 2023-2024 | |
| Celgene Corporation | $175.25 | 2022-2025 | Reblozyl, Pomalyst |
| Abbvie INC. | $143.34 | 2021-2025 | |
| Adc Therapeutics America, INC. | $117.68 | 2021-2025 | |
| Gilead Sciences, INC. | $98.17 | 2022-2024 | Trodelvy |
| Array Biopharma INC | $96.46 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $91.34 | 2021-2025 | Ninlaro |
| Myriad Genetic Laboratories, INC. | $88.19 | 2021-2024 | Myrisk |
| Beigene USA, INC. | $74.79 | 2023-2024 | Brukinsa |
| Eisai INC. | $68.08 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $64.43 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $61.79 | 2024 | Onivyde |
| Astellas Pharma US INC | $58.31 | 2022-2025 | Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $56.37 | 2022-2023 | |
| Morphosys, US INC. | $50.11 | 2022-2023 | Monjuvi |
| Axonics, INC. | $44.92 | 2024 | Axonics |
| Emmaus Medical, INC. | $44.40 | 2021-2024 | Endari |
| Pharmacosmos Therapeutics INC. | $41.20 | 2024-2025 | Monoferric, Cosela |
| Aveo Pharmaceuticals, INC. | $39.27 | 2025 | |
| Alexion Pharmaceuticals, INC. | $33.57 | 2024-2025 | Ultomiris |
| Sumitomo Pharma America, INC. | $33.23 | 2024-2025 | Orgovyx |
| Jazz Pharmaceuticals INC. | $32.12 | 2025 | |
| Blueprint Medicines Corporation | $31.49 | 2022-2023 | Ayvakit |
| Geron Corporation | $29.00 | 2024-2025 | Rytelo |
| Sun Pharmaceutical Industries INC. | $28.96 | 2025 | |
| Emd Serono, INC. | $28.07 | 2024 | |
| Lilly USA, LLC | $24.37 | 2024 | Verzenio |
| Deciphera Pharmaceuticals INC. | $22.01 | 2025 | Tgct, Qinlock |
| Beone Medicines USA, INC. | $21.09 | 2025 | Brukinsa |
| Recordati_rare_diseases_inc. | $19.27 | 2025 | Enjaymo |
| Coherus Oncology, INC. | $15.86 | 2025 | Loqtorzi |
| Genentech USA, INC. | $15.69 | 2025 | Itovebi |
| Fennec Pharmaceuticals, INC. | $15.03 | 2025 | Fyarro |
| Clovis Oncology, INC. | $13.92 | 2021 | |
| Medicomp INC | $13.75 | 2023 | Telepatch Cardiac Monitor |
| G1 Therapeutics, INC. | $12.79 | 2022 | |
| Myovant Sciences INC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenifer Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.